Cargando…
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625163/ https://www.ncbi.nlm.nih.gov/pubmed/28971619 http://dx.doi.org/10.1002/prp2.359 |
_version_ | 1783268348969091072 |
---|---|
author | Chan, Christina Martin, Philip Liptrott, Neill J. Siccardi, Marco Almond, Lisa Owen, Andrew |
author_facet | Chan, Christina Martin, Philip Liptrott, Neill J. Siccardi, Marco Almond, Lisa Owen, Andrew |
author_sort | Chan, Christina |
collection | PubMed |
description | Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine, and puromycin were assessed individually, and in two‐, three‐, and four‐drug combinations for protein synthesis inhibition (IC (50)) and cytotoxicity (CC (50)) over 72 h. Experiments were conducted in HepG2 cells and primary rat hepatocytes (PRH). IC (50) for actinomycin D, cycloheximide, emetine, and puromycin were 39 ± 7.4, 6600 ± 2500, 2200 ± 1400, and 1600 ± 1200 nmol/L; with corresponding CC (50) values of 6.2 ± 7.3, 570 ± 510, 81 ± 9, and 1300 ± 64 nmol/L, respectively, in HepG2 cells. The IC (50) were 1.7 ± 1.8, 290 ± 90, 620 ± 920, and 2000 ± 2000 nmol/L, with corresponding CC (50) values of 0.98 ± 1.8, 680 ± 1300, 180 ± 700, and 1600 ± 1000 (SD) nmol/L, respectively, in PRH. CC (50) were also lower than the IC (50) for all drug combinations in HepG2 cells. These data indicate that using pharmacological interference is inappropriate for measuring protein degradation over a protracted period, because inhibitory effects cannot be extricated from cytotoxicity. |
format | Online Article Text |
id | pubmed-5625163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56251632017-10-04 Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates Chan, Christina Martin, Philip Liptrott, Neill J. Siccardi, Marco Almond, Lisa Owen, Andrew Pharmacol Res Perspect Original Articles Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine, and puromycin were assessed individually, and in two‐, three‐, and four‐drug combinations for protein synthesis inhibition (IC (50)) and cytotoxicity (CC (50)) over 72 h. Experiments were conducted in HepG2 cells and primary rat hepatocytes (PRH). IC (50) for actinomycin D, cycloheximide, emetine, and puromycin were 39 ± 7.4, 6600 ± 2500, 2200 ± 1400, and 1600 ± 1200 nmol/L; with corresponding CC (50) values of 6.2 ± 7.3, 570 ± 510, 81 ± 9, and 1300 ± 64 nmol/L, respectively, in HepG2 cells. The IC (50) were 1.7 ± 1.8, 290 ± 90, 620 ± 920, and 2000 ± 2000 nmol/L, with corresponding CC (50) values of 0.98 ± 1.8, 680 ± 1300, 180 ± 700, and 1600 ± 1000 (SD) nmol/L, respectively, in PRH. CC (50) were also lower than the IC (50) for all drug combinations in HepG2 cells. These data indicate that using pharmacological interference is inappropriate for measuring protein degradation over a protracted period, because inhibitory effects cannot be extricated from cytotoxicity. John Wiley and Sons Inc. 2017-09-29 /pmc/articles/PMC5625163/ /pubmed/28971619 http://dx.doi.org/10.1002/prp2.359 Text en © 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Chan, Christina Martin, Philip Liptrott, Neill J. Siccardi, Marco Almond, Lisa Owen, Andrew Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title_full | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title_fullStr | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title_full_unstemmed | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title_short | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
title_sort | incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625163/ https://www.ncbi.nlm.nih.gov/pubmed/28971619 http://dx.doi.org/10.1002/prp2.359 |
work_keys_str_mv | AT chanchristina incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates AT martinphilip incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates AT liptrottneillj incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates AT siccardimarco incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates AT almondlisa incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates AT owenandrew incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates |